Haematologica (Oct 2019)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

  • Peter Valent,
  • Attilio Orazi,
  • Michael R. Savona,
  • Mrinal M. Patnaik,
  • Francesco Onida,
  • Arjan A. van de Loosdrecht,
  • Detlef Haase,
  • Torsten Haferlach,
  • Chiara Elena,
  • Lisa Pleyer,
  • Wolfgang Kern,
  • Tea Pemovska,
  • Gregory I. Vladimer,
  • Julie Schanz,
  • Alexandra Keller,
  • Michael Lübbert,
  • Thomas Lion,
  • Karl Sotlar,
  • Andreas Reiter,
  • Theo De Witte,
  • Michael Pfeilstöcker,
  • Klaus Geissler,
  • Eric Padron,
  • Michael Deininger,
  • Alberto Orfao,
  • Hans-Peter Horny,
  • Peter L. Greenberg,
  • Daniel A. Arber,
  • Luca Malcovati,
  • John M. Bennett

DOI
https://doi.org/10.3324/haematol.2019.222059
Journal volume & issue
Vol. 104, no. 10

Abstract

Read online

Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past two decades, our knowledge about the pathogenesis and molecular mechanisms in CMML has increased substantially. In parallel, better diagnostic criteria and therapeutic strategies have been developed. However, many questions remain regarding prognostication and optimal therapy. In addition, there is a need to define potential pre-phases of CMML and special CMML variants, and to separate these entities from each other and from conditions mimicking CMML. To address these unmet needs, an international consensus group met in a Working Conference in August 2018 and discussed open questions and issues around CMML, its variants, and pre-CMML conditions. The outcomes of this meeting are summarized herein and include diag nostic criteria and a proposed classification of pre-CMML conditions as well as refined minimal diagnostic criteria for classical CMML and special CMML variants, including oligomonocytic CMML and CMML associated with systemic mastocytosis. Moreover, we propose diagnostic standards and tools to distinguish between ‘normal’, pre-CMML and CMML entities. These criteria and standards should facilitate diagnostic and prognostic evaluations in daily practice and clinical studies in applied hematology.